Navigation Links
Luminex Technology Selected by Assurex Health
Date:3/12/2015

AUSTIN, Texas, March, 12, 2015 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that its xTAG® Technology has been selected for use in enhancing the processing speed and capacity of Assurex Health's patented GeneSight® tests. 

Healthcare providers use GeneSight to help patients affected by neuropsychiatric conditions including depression, posttraumatic stress disorder (PTSD), anxiety, bipolar disorder, schizophrenia, ADHD, and acute and chronic pain. 

This agreement incorporates Luminex's open-architecture xTAG Technology into the GeneSight testing process and enables large numbers of tests to be conducted and analyzed quickly, cost-effectively, and accurately.

"With our unique portfolio of pharmacogenetics assays, flexible platforms, and support, Luminex is delighted to be selected as the partner of choice by Assurex Health," said Homi Shamir, President and CEO of Luminex. "Assurex Health is at the forefront of the fast-growing field of personalized medicine, and we are excited that our technology will be a part of this solution. We look forward to partnering with Assurex Health in their goal of helping clinicians determine the right therapeutics for their patients."

"Luminex's highly sensitive xTAG Technology will improve our workflow efficiency without increasing cost," said Donald R. Wright, Executive Vice President and Chief Operating Officer, Assurex Health. "In addition, the flexibility of the Luminex platform will allow us to add new biomarkers as our needs continue to expand."

Pharmacogenetics Innovation at Luminex
Luminex launched its first test to aid in personalized medicine in 2010. Since that time, Luminex has received Health Canada Approval, U.S. FDA clearance, and European clearance for its xTAG CYP2D6 Kit v3 and xTAG CYP2C19 Kit v3 assays. Luminex is a member of the Personalized Medicine Coalition.

For more information on Luminex's pharmacogenetic assays, visit: www.luminexcorp.com/CYP2D6 or www.luminexcorp.com/CYP2C19.

Learn more about the Personalized Medicine Coalition: http://www.personalizedmedicinecoalition.org/

About Luminex Corporation
Luminex is committed to applying its passion for innovation toward creating breakthrough solutions to improve health and advance science. The company is transforming global healthcare and life-science research through the development, manufacturing and marketing of proprietary instruments and assays utilizing xMAP® open-architecture multi-analyte platform, MultiCode® real-time polymerase chain reaction (PCR), and multiplex PCR-based technologies, that deliver cost-effective rapid results to clinicians and researchers. Luminex's technology is commercially available worldwide and in use in leading clinical laboratories, as well as major pharmaceutical, diagnostic, biotechnology and life-science companies. Luminex is meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, biodefense research, and food safety. For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology, please visit http://www.luminexcorp.com/.

About Assurex Health
Assurex Health is a commercial-stage, informatics-based, precision medicine company providing treatment decision support to clinicians for behavioral health conditions. Assurex Health's proprietary GeneSight technology is based on combinatorial pharmacogenomics (CPGxTM) – the study of the genetic factors that influence an individual's response to medications, including evidence-based medicine and clinical pharmacology.  Assurex Health has licensed patented technology from Mayo Clinic and Cincinnati Children's Hospital Medical Center, both of whom continue to be research collaborators.  Learn more at www.assurexhealth.com  

Contacts
Luminex Investor Contact
Harriss Currie
Sr. Vice President of Finance and CFO
512.219.8020
hcurrie@luminexcorp.com

Luminex Media Contact
Christine Valle
Sr. Manager, Global Marketing
512.219.8020
cvalle@luminexcorp.com

Disclaimer: The financial terms of the multi-year agreement were not disclosed.

Logo - http://photos.prnewswire.com/prnh/20150201/172702LOGO


'/>"/>
SOURCE Luminex Corporation
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Luminex Corporation To Present At Cowen And Company 35th Annual Health Care Conference
2. Luminex Corporation Announces Retirement of Patrick Balthrop, President and CEO
3. Luminex Corporation Third Quarter Earnings Release Scheduled for October 27, 2014
4. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
5. Luminex Is Supporting U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) in Research Efforts to Control African Ebola Outbreak
6. Luminex Corporation Reports Second Quarter 2014 results
7. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
8. Luminex Corporation Reports Third Quarter 2013 Results
9. LUMINEX CORPORATION TO HOST INVESTOR EVENT AT ASSOCIATION FOR MOLECULAR PATHOLOGY ANNUAL MEETING
10. Luminex Corporation To Present At Morgan Stanley Global Healthcare Conference
11. Luminex Corporation Reports Second Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/8/2019)... ... 08, 2019 , ... A free, interactive event highlighting innovations and ideas helping ... event, featuring thought leaders, innovators and health experts, will display innovations that could help ... to 5:30 p.m. CT on October 19 at the Coppertank Event Center in Austin, ...
(Date:10/8/2019)... , ... October 08, 2019 , ... ... for the healthcare segment at the Healthcare Design Expo (HCD) from Nov. 3-5, ... for healthcare facilities for over 35 years. Since its installation in the early ...
(Date:10/8/2019)... INDIANAPOLIS (PRWEB) , ... October 08, 2019 , ... ... aims to provide farmers a wider range of novel, microbial-based crop protection products. ... identification of new natural product starting points. In a first for the agriculture ...
Breaking Medicine Technology:
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... METAvivor Research ... breast cancer, announced the launch of its Stage IV Stampede campaign. The campaign will ... in Washington, DC that will include an advocacy boot camp, a march, a Die-In ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. ... has recently attended an advanced Level III training in Cagliari, Italy, this past ... training took place September 16-19, 2019 at the Sardinia Dental Teaching Center and ...
(Date:10/8/2019)... , ... October 08, 2019 , ... ... headquartered in Irving, Texas, that exclusively serves premier oral and maxillofacial surgeons – ... oral and maxillofacial surgery practice with two locations near Knoxville, Tennessee. The partnership ...
(Date:10/8/2019)... ... 08, 2019 , ... Continuing its leading research on human ... Care4U™ 2’-FL, a DuPont product, beneficially changes microbiota composition and the production of ... microbiota and metabolite composition by 2’-FL were between the responses elicited by GOS ...
(Date:10/8/2019)... ... October 08, 2019 , ... ... is pleased to announce the addition of Brenda Thomas, an industry professional with ... Account Manager for the Professional Services Plans dental team at Brown & Brown ...
Breaking Medicine News(10 mins):